{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:43:29Z","timestamp":1790480609791,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kyowa Kirin Co.,Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bardoxolone methyl activates the Keap1\/Nrf2 system that plays an important role in defense responses against oxidative stress. Importantly, bardoxolone methyl has demonstrated increases in estimated glomerular filtration rate (eGFR) in patients with diabetic kidney disease (DKD) in clinical studies. However, an overseas Phase 3 study of bardoxolone methyl in patients with stage G4 DKD was prematurely terminated due to an increased risk for heart failure, which was considered to have been caused by early-onset fluid overload. Subsequently, a Japanese Phase 2 study demonstrated, for the first time, that bardoxolone methyl directly improves GFR, which is a true indicator of kidney function, using the inulin clearance method. In Japan, bardoxolone methyl was designated for the treatment of DKD under the Priority Review and Designation (SAKIGAKE Designation) System established by the Ministry of Health, Labour and Welfare. A Japanese Phase 3 study, with endpoints such as a\u2009\u2265\u200930% decrease in eGFR, is currently ongoing to assess the efficacy and safety of bardoxolone methyl in more than 1,000 patients with stages G3 and G4 DKD who have no identified risk factors.<\/jats:p>","DOI":"10.1007\/s10157-020-01917-5","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T07:03:14Z","timestamp":1593241394000},"page":"857-864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Bardoxolone methyl: drug development for diabetic kidney disease"],"prefix":"10.1007","volume":"24","author":[{"given":"Hironori","family":"Kanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Yamawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,27]]},"reference":[{"key":"1917_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4009\/jsdt.51.699","volume":"51","author":"K Nitta","year":"2018","unstructured":"Nitta K, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, Nakai S, et al. 2017 annual dialysis data report, JSDT renal data registry. J Jpn Soc Dial Ther. 2018;51:699\u201376666.","journal-title":"J Jpn Soc Dial Ther"},{"key":"1917_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.ajkd.2009.05.011","volume":"54","author":"T Akizawa","year":"2009","unstructured":"Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009;54:459\u201367.","journal-title":"Am J Kidney Dis"},{"key":"1917_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80:282\u20137.","journal-title":"Kidney Int"},{"key":"1917_CR4","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2014010042","volume":"26","author":"G Schulman","year":"2015","unstructured":"Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, et al. Randomized placebo-controlled eppic trials of AST-120 in CKD. J Am Soc Nephrol. 2015;26:1732\u201346.","journal-title":"J Am Soc Nephrol"},{"key":"1917_CR5","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201342.","journal-title":"N Engl J Med"},{"key":"1917_CR6","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1124\/pr.111.004846","volume":"64","author":"KT Liby","year":"2012","unstructured":"Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev. 2012;64:972\u20131003.","journal-title":"Pharmacol Rev"},{"key":"1917_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","volume":"98","author":"M Yamamoto","year":"2018","unstructured":"Yamamoto M, Kensler TW, Motohashi H. The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol Rev. 2018;98:1169\u2013203.","journal-title":"Physiol Rev"},{"key":"1917_CR8","doi-asserted-by":"publisher","first-page":"9926","DOI":"10.1073\/pnas.91.21.9926","volume":"91","author":"P Moi","year":"1994","unstructured":"Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2\/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci. 1994;91:9926\u201330.","journal-title":"Proc Natl Acad Sci"},{"key":"1917_CR9","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.6970.1","volume":"4","author":"J Yamaguchi","year":"2015","unstructured":"Yamaguchi J, Tanaka T, Nangaku M. Recent advances in understanding of chronic kidney disease. F1000Res. 2015;4:F1000 Faculty Rev-1212.","journal-title":"F1000Res"},{"key":"1917_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/dmrr.717","volume":"23","author":"C Giannini","year":"2007","unstructured":"Giannini C, Lombardo F, Curr\u00f2 F, Pomilio M, Bucciarelli T, Chiarelli F, et al. Effects of high-dose vitamin E supplementation on oxidative stress and microalbuminuria in young adult patients with childhood onset type 1 diabetes mellitus. Diabetes Metab Res Rev. 2007;23:539\u201346.","journal-title":"Diabetes Metab Res Rev."},{"key":"1917_CR11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3109\/0886022X.2013.826110","volume":"35","author":"SO Grebe","year":"2013","unstructured":"Grebe SO, Langenbeck M, Schaper A, Berndt S, Aresmouk D, Herget-Rosenthal S. Antioxidant treatment and outcome of Cortinarius orellanus poisoning: a case series. Ren Fail. 2013;35:1436\u20139.","journal-title":"Ren Fail"},{"key":"1917_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/13590840020013266","volume":"10","author":"RB Singh","year":"2000","unstructured":"Singh RB, Khanna HK, Niaz MA. Randomized, double-blind placebo-controlled trial of coenzyme q10 in chronic renal failure: discovery of a new role. J Nutr Environ Med. 2000;10:281\u20138.","journal-title":"J Nutr Environ Med"},{"key":"1917_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000475890","volume":"45","author":"M Nezu","year":"2017","unstructured":"Nezu M, Suzuki N, Yamamoto M. Targeting the KEAP1-NRF2 system to prevent kidney disease progression. Am J Nephrol. 2017;45:473\u201383.","journal-title":"Am J Nephrol"},{"key":"1917_CR14","doi-asserted-by":"publisher","first-page":"F662","DOI":"10.1152\/ajprenal.00421.2009","volume":"298","author":"HJ Kim","year":"2010","unstructured":"Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol. 2010;298:F662\u201371.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1917_CR15","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1681\/ASN.2013080906","volume":"25","author":"S Martini","year":"2014","unstructured":"Martini S, Nair V, Keller BJ, Eichinger F, Hawkins JJ, Randolph A, et al. Integrative biology identifies shared transcriptional networks in CKD. J Am Soc Nephrol. 2014;25:2559\u2013722.","journal-title":"J Am Soc Nephrol"},{"key":"1917_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.taap.2018.09.030","volume":"360","author":"K Yamawaki","year":"2018","unstructured":"Yamawaki K, Kanda H, Shimazaki R. Nrf2 activator for the treatment of kidney diseases. Toxicol Appl Pharmacol. 2018;360:30\u20137.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1917_CR17","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-11-2703","volume":"18","author":"DS Hong","year":"2012","unstructured":"Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012;18:3396\u2013406.","journal-title":"Clin Cancer Res"},{"key":"1917_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1105351","volume":"365","author":"PE Pergola","year":"2011","unstructured":"Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365:327\u201336.","journal-title":"N Engl J Med"},{"key":"1917_CR19","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","volume":"369","author":"D de Zeeuw","year":"2013","unstructured":"de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492\u2013503.","journal-title":"N Engl J Med"},{"key":"1917_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1159\/000362906","volume":"39","author":"MP Chin","year":"2014","unstructured":"Chin MP, Reisman SA, Bakris GL, O'Grady M, Linde PG, McCullough PA, et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol. 2014;39:499\u2013508.","journal-title":"Am J Nephrol"},{"key":"1917_CR21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","volume":"20","author":"MP Chin","year":"2014","unstructured":"Chin MP, Wrolstad D, Bakris GL, Chertow GM, de Zeeuw D, Goldsberry A, et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014;20:953\u20138.","journal-title":"J Card Fail"},{"key":"1917_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000486398","volume":"47","author":"MP Chin","year":"2018","unstructured":"Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, et al. Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes: post-hoc analyses from bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 Diabetes study. Am J Nephrol. 2018;47:40\u20137.","journal-title":"Am J Nephrol"},{"key":"1917_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.kint.2016.09.015","volume":"91","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91:227\u201334.","journal-title":"Kidney Int"},{"key":"1917_CR24","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","volume":"5","author":"M Nangaku","year":"2020","unstructured":"Nangaku M, Kanda H, Takama H, Ichikawa T, Hase H, Akizawa T. Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study). Kidney Int Rep. 2020;5:879\u201390.","journal-title":"Kidney Int Rep"},{"key":"1917_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/ki.2012.393","volume":"83","author":"Y Ding","year":"2013","unstructured":"Ding Y, Stidham RD, Bumeister R, Trevino I, Winters A, Sprouse M, et al. The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells. Kidney Int. 2013;83:845\u201354.","journal-title":"Kidney Int"},{"key":"1917_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.redox.2013.10.007","volume":"1","author":"MA Aminzadeh","year":"2013","unstructured":"Aminzadeh MA, Reisman SA, Vaziri ND, Shelkovnikov S, Farzaneh SH, Khazaeli M, et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease. Redox Biol. 2013;1:527\u201331.","journal-title":"Redox Biol"},{"key":"1917_CR27","doi-asserted-by":"publisher","first-page":"31579","DOI":"10.1074\/jbc.M109.009175","volume":"284","author":"EH Heiss","year":"2009","unstructured":"Heiss EH, Schachner D, Werner ER, Dirsch VM. Active NF-E2-related factor (Nrf2) contributes to keep endothelial NO synthase (eNOS) in the coupled state: role of reactive oxygen species (ROS), eNOS, and heme oxygenase (HO-1) levels. J Biol Chem. 2009;284:31579\u201386.","journal-title":"J Biol Chem"},{"key":"1917_CR28","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719\u201328.","journal-title":"JAMA"},{"key":"1917_CR29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.amjhyper.2003.07.017","volume":"16","author":"C Delles","year":"2003","unstructured":"Delles C, Klingbeil AU, Schneider MP, Handrock R, Weidinger G, Schmieder RE. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens. 2003;16:1030\u20135.","journal-title":"Am J Hypertens"},{"key":"1917_CR30","first-page":"378","volume":"1","author":"K Kidokoro","year":"2019","unstructured":"Kidokoro K, Nagasu H, Satoh M, Meyer CJ, Kashihara N. Activation of the Keap1\/Nrf2 pathway increases GFR by increasing glomerular effective filtration area without affecting the afferent\/efferent arteriole ratio. J Am Soc Nephrol. 2019;1:378.","journal-title":"J Am Soc Nephrol"},{"key":"1917_CR31","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3109\/00498254.2013.852705","volume":"44","author":"MA Aminzadeh","year":"2014","unstructured":"Aminzadeh MA, Reisman SA, Vaziri ND, Khazaeli M, Yuan J, Meyer CJ. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica. 2014;44:570\u20138.","journal-title":"Xenobiotica"},{"key":"1917_CR32","doi-asserted-by":"publisher","first-page":"12253","DOI":"10.1096\/fj.201900217R","volume":"33","author":"H Nagasu","year":"2019","unstructured":"Nagasu H, Sogawa Y, Kidokoro K, Itano S, Yamamoto T, Satoh M, et al. Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function. FASEB J. 2019;33:12253\u201363.","journal-title":"FASEB J"},{"key":"1917_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.9734\/JALSI\/2015\/13745","volume":"2","author":"Y Son","year":"2015","unstructured":"Son Y, Liu S, Farzaneh SH, Nazertehrani S, Khazaeli M, Vaziri ND. Activation of Nrf2 restores klotho expression and attenuates oxidative stress and inflammation in CKD. J Appl Life Sci Int. 2015;2:22\u201334.","journal-title":"J Appl Life Sci Int"},{"key":"1917_CR34","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.2337\/db13-1743","volume":"63","author":"SM Tan","year":"2014","unstructured":"Tan SM, Sharma A, Stefanovic N, Yuen DY, Karagiannis TC, Meyer C, et al. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetes. 2014;63:3091\u2013103.","journal-title":"Diabetes"},{"key":"1917_CR35","doi-asserted-by":"publisher","first-page":"F1438","DOI":"10.1152\/ajprenal.00387.2012","volume":"304","author":"M Chin","year":"2013","unstructured":"Chin M, Lee CY, Chuang JC, Bumeister R, Wigley WC, Sonis ST, et al. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity. Am J Physiol Renal Physiol. 2013;304:F1438\u201346.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1917_CR36","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1007\/s10157-018-1615-x","volume":"22","author":"E Kanda","year":"2018","unstructured":"Kanda E, Kashihara N, Matsushita K, Usui T, Okada H, Iseki K, et al. Guidelines for clinical evaluation of chronic kidney disease: AMED research on regulatory science of pharmaceuticals and medical devices. Clin Exp Nephrol. 2018;22:1446\u201375.","journal-title":"Clin Exp Nephrol"},{"key":"1917_CR37","unstructured":"Reata Pharmaceuticals, Inc. News Release. Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome. https:\/\/www.reatapharma.com\/wp-content\/uploads\/2019\/11\/CARDINAL-P3-Data-Release-FINAL-AFTER-QC.pdf. Accessed 17 Mar 2020."},{"key":"1917_CR38","unstructured":"Ministry of Health, Labor and Welfare. A July 2018 report. https:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000172968_00002.html. Accessed 17 Mar 2020."}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01917-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-020-01917-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01917-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T19:44:31Z","timestamp":1624736671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-020-01917-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,27]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1917"],"URL":"https:\/\/doi.org\/10.1007\/s10157-020-01917-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,27]]},"assertion":[{"value":"11 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors are employees of Kyowa Kirin Co., Ltd., which has the exclusive rights to develop and commercialize bardoxolone methyl in kidney disease and other indications in Japan, China, Taiwan, South Korea, and Southeast Asia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}]}}